Enzyme immunoassay for the quantification of mithramycin using beta-D-galactosidase as a label.

A sensitive enzyme immunoassay for mithramycin (MTM) has been developed by using antibody induced in rabbits, beta-D-galactosidase-labeled MTM, and a double-antibody separation technique, which allowed us to measure accurately as little as 100 pg of MTM per assay tube. MTM-antibody was produced against MTM-bovine serum albumin conjugate prepared by the use of diazotized p-aminobenzoic acid as a cross-linker. The beta-D-galactosidase-labeled MTM conjugate was similarly prepared by a geometric m-isomer of diazotized aminobenzoic acid. This enzyme immunoassay was specific to MTM and showed a very slight cross-reactivity with MTM analogues, chromomycin A3 (5.6%) and olivomycin (2.4%), but no cross-reactivity with drugs commonly used with MTM in combination chemotherapy for cancer treatment. The values of MTM concentrations detected by this assay were comparable to those detected by the high-pressure liquid chromatography method. However, the enzyme immunoassay method was 100 times more sensitive in detecting MTM in lower concentrations. Using this assay, drug levels were easily determined in the blood and urine of rats during 6 h after i.v. administration of MTM in a single dose of 2.0 mg/kg. Since MTM has long been used against a variety of human cancers, the enzyme immunoassay of the drug will be a valuable new tool in clinical pharmacological studies.

[1]  K. Fujiwara,et al.  Development of enzyme immunoassay for chromomycin A3 and olivomycin using beta-D-galactosidase as a label. , 1985, Cancer research.

[2]  K. Hara,et al.  Development and application of a sensitive enzyme immunoassay for 7-N-(p-hydroxyphenyl)mitomycin C. , 1984, Cancer research.

[3]  K. Fujiwara,et al.  Enzyme immunoassay for pepleomycin, a new bleomycin analog. , 1981, Cancer Research.

[4]  Trofimova Nb.  Trial of the clinical use of mithramycin in treating testicular cancer , 1980 .

[5]  H. R. Lindner,et al.  Steroids as haptens: Optimal design of antigens for the formation of antibodies to steroid hormones , 1974 .

[6]  N. Sedransk,et al.  Mithramycin (NSC 24559) therapy of testicular tumors , 1972, Cancer.

[7]  P. Lomax,et al.  Antibody detection of marihuana. , 1972, Nature: New biology.

[8]  B. Kennedy.  Metabolic and toxic effects of mithramycin during tumor therapy. , 1970, The American journal of medicine.

[9]  W. C. Levin,et al.  Observations on the mechanism of hemorrhagic toxicity in mithramycin (NSC 24559) therapy. , 1969, Cancer research.

[10]  G. W. Anderson,et al.  A reinvestigation of the mixed carbonic anhydride method of peptide synthesis. , 1967, Journal of the American Chemical Society.

[11]  B. Kennedy,et al.  Studies with tritiated mithramycin in C3H mice. , 1967, Cancer research.

[12]  C. Anfinsen,et al.  PURIFICATION, COMPOSITION, AND MOLECULAR WEIGHT OF THE BETA-GALACTOSIDASE OF ESCHERICHIA COLI K12. , 1965, The Journal of biological chemistry.

[13]  Rao Kv,et al.  A new antibiotic with antitumor properties. , 1962 .

[14]  M. Slavik,et al.  Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. , 1975, Advances in pharmacology and chemotherapy.

[15]  G. F. Woods,et al.  Specificities of antisera against testosterone linked to albumin at different positions (C3, C11, C17). , 1974, Steroids.

[16]  Y. Berlin,et al.  The structure of aureolic acid (mithramycin). , 1968, Tetrahedron letters.

[17]  B. Kennedy,et al.  Effect of mithramycin on a mouse glioma. , 1968, Cancer research.

[18]  K. V. Rao,et al.  A new antibiotic with antitumor properties. , 1962, Antibiotics & chemotherapy.